New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma

On September 10, the Mesothelioma Applied Research Foundation will host a new installment of its Meet the Mesothelioma Experts live broadcast, featuring Stephen Isaacs, the chairperson, president and CEO of Aduro BioTech, discussing the company’s new mesothelioma clinical trial, which uses a modified Listeria virus.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Mesothelioma Applied Research Foundation Logo
The focus of the interview will be Aduro BioTech’s experimental therapy for malignant pleural mesothelioma, which uses a weakened form of the Listeria virus to stimulate the immune system.

Alexandria, VA (PRWEB) August 28, 2014

On September 10, the Mesothelioma Applied Research Foundation (Meso Foundation) will interview Stephen Isaacs, the chairperson, president and CEO of Aduro BioTech, during a new installment of the Foundation’s Meet the Mesothelioma Experts live broadcast. The interview will be led by the Meso Foundation’s executive director and mesothelioma expert nurse practitioner, Mary Hesdorffer, APRN.

The focus of the interview will be Aduro BioTech’s experimental therapy for malignant pleural mesothelioma, known as CRS-207. CRS-207 is a weakened form of the Listeria virus modified to reduce its ability to cause infections, but still able to stimulate the immune system.

The interview will be available live on September 10, at 1 PM ET, by calling into a conference-call number. The interview is free of charge, but listeners must RSVP ahead of time by visiting http://www.curemeso.org/experts in order to receive a call-in number.

In his position at Aduro BioTech, Mr. Isaacs initiated the company’s current immunotherapy program based on attenuated strains of Listeria monocytogenes. He was responsible for recruiting key members of the current vaccine team with deep expertise in the biology of Listeria. Mr. Isaacs has published over 20 peer-reviewed scientific articles and is an inventor on over 40 issued patents.

Mesothelioma is a malignant tumor of the lining of the lung, abdomen, or heart known to be caused by exposure to asbestos. With the life expectancy of less than one year after diagnosis, medical experts consider it one of the most aggressive and deadly of all cancers. An estimated one-third of those who develop mesothelioma were exposed while serving in the Navy or working in shipyards. Currently, few treatment options exist. There is no cure.

ABOUT THE MESOTHELIOMA APPLIED RESEARCH FOUNDATION
The Meso Foundation is the only 501(c)(3) nonprofit organization dedicated to eradicating mesothelioma and easing the suffering caused by this cancer. The Meso Foundation actively seeks philanthropic support to fund mesothelioma research; provide patient support services and education; and advocate Congress for increased federal funding for mesothelioma research. The Meso Foundation is the only non-government funder of peer-reviewed scientific research to develop life-saving treatments for this extremely aggressive cancer. To date, the Foundation has awarded over $8.7 million to research. More information is available at http://www.curemeso.org.

###